A drug for improving the activity of dopamine neurons in the substantia nigra of the midbrain and preventing and treating Parkinson's disease

A Parkinson's disease and neuron technology, applied in the field of biomedicine, can solve the problems of lack of fulvestrant, reduced buffering ability of exogenous dopamine drugs, loss of ability to produce dopamine, etc., and achieve the effect of restoring neuron activity

Active Publication Date: 2022-02-22
SUN YAT SEN MEMORIAL HOSPITAL SUN YAT SEN UNIV
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, with the continuous development of PD and continuous levodopa administration, the ability of the remaining dopaminergic neurons to produce dopamine is lost, and the buffering ability of exogenous dopamine drugs is reduced.
There are no reports related to the treatment of fulvestrant and Parkinson's disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A drug for improving the activity of dopamine neurons in the substantia nigra of the midbrain and preventing and treating Parkinson's disease
  • A drug for improving the activity of dopamine neurons in the substantia nigra of the midbrain and preventing and treating Parkinson's disease
  • A drug for improving the activity of dopamine neurons in the substantia nigra of the midbrain and preventing and treating Parkinson's disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] This embodiment provides a method for screening and improving the activity of dopamine neurons in the substantia nigra of the midbrain to prevent and treat Parkinson's disease, comprising the following steps:

[0033] S1. Gene expression data collection:

[0034] Gene expression data were obtained from public GEO data. GEO datasets contain microarray, next-generation sequencing, and other forms of high-throughput genomic data submitted by research scholars. From GEO, we downloaded 6 genome-wide gene expression data sets, namely gene expression data of 10 brain regions (GSE60862), spatiotemporal gene expression data (GSE25219), normal human brain tissue gene expression data (GSE45878, GSE34865) , Parkinson's disease case-control gene expression data (GSE8397) and mouse brain gene expression data (GSE16496).

[0035] S2. Construction of normal human brain co-expression network:

[0036]A gene co-expression network was constructed using the GSE60862 dataset. Genes in 1...

Embodiment 2

[0059] Example 2 Fulvestrant cell experiment proof

[0060] 1. Fulvestrant can inhibit the down-regulation of PD gene

[0061] The rotenone-induced Parkinson's disease model in Step 7 of Example 1 was used to verify the effect of fulvestrant on the PD gene. In the rotenone-induced Parkinson's disease model, the inventors treated cortical neurons with five treatments of DMSO, CCCP, ROT400nM, ROT400nM+FUL200nM and FUL200nM. First, cortical neurons were pretreated with 200nm rotenone for 2 hours, and then treated with different concentrations (100nm, 200nm and 300nm) of fulvestrant for 24 hours. Cortical neurons treated with CN (control group), DMSO (2%), rotenone and different concentrations (100nM, 200nM and 300nM) of fulvestrant were detected by RT-qPCR method. The purpose of the DMSO treatment was to test the effect of the solvent. Statistical analysis was performed using GraphPad Prism 7.0 software.

[0062] The result is as figure 1 As shown, after treating the Parkins...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a drug for preventing and treating Parkinson's disease by improving the activity of dopamine neurons in the substantia nigra of the midbrain. The drug is fulvestrant. The present invention also provides a method for screening and improving the activity of dopamine neurons in the substantia nigra of the midbrain to prevent and treat Parkinson's disease. The weighted gene co-expression network analysis and the bioinformatics method of identifying the differential co-expression modules related to biology are used to combine and The genes closely related to Parkinson's disease are matched to the gene network module, and the gene co-expression module related to Parkinson's disease is obtained, and through the correlation map database and the samples from the substantia nigra of the Parkinson's disease and the normal control group Differential gene expression profile data of different genes were screened to obtain drugs that can significantly reverse the abnormally expressed genes in the module. The present invention overcomes the limitation of a single pathway or target, and also uses the CMAP database to screen approved clinical drugs, saving time, money, and labor costs, and is more conducive to the development of safe and effective drugs.

Description

technical field [0001] The invention belongs to the field of biomedicine, and specifically relates to screening a drug for improving the activity of dopamine neurons in the substantia nigra of the midbrain and preventing and treating Parkinson's disease through bioinformatics methods. Background technique [0002] Parkinson's disease (PD) is a degenerative disease of the central nervous system characterized by degeneration and necrosis of dopamine neurons in the substantia nigra of the midbrain. Increased height, slow movement, etc. Although PD has been studied for nearly 200 years, so far, due to the unclear pathogenesis of PD, no matter whether drug therapy or surgical treatment can only improve the symptoms of the disease, it cannot prevent the development of the disease, let alone prevent it. cure. [0003] Pathologically, the degeneration of dopamine (DA) neurons in the substantia nigra reticular zone and the decrease of striatal DA levels can be seen in the pathology...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): G16B20/20G16H70/40A61K31/565A61P25/16
CPCG16B20/20G16H70/40A61K31/565A61P25/16
Inventor 赵慧英范世超
Owner SUN YAT SEN MEMORIAL HOSPITAL SUN YAT SEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap